ATTRibute-CM data show acoramidis reduced mortality in ATTRwt-CM and ATTRv-CM and raised serum transthyretin through 42 months.
Ryan Livingston
Advertisement
Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.
Articles by Ryan Livingston
Phase 3 OCEANIC-STROKE data show how asundexian offers a potential new secondary stroke prevention option.
Papillary muscle scarring has a substantial association with both cardiovascular mortality and arrhythmia.
Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Clinicians Cite Progress Tracking as Top Barrier in Value-Based Care
2
T-DXd Delivers Strong Breast Cancer Outcomes Across Groups
3
Genome-Wide Analysis Uncovers Genetic Drivers of IPF and Its Overlap With COVID-19
4
Experts Warn Binge Drinking Drives Early-Onset Breast Cancer, While Cessation Reduces Risk
5
